Elbrus invests in Active Component

Following the investment from Elbrus Capital Fund II, the majority stake in the company will be retained by its founders.

Active Component is planning to use the funding for the construction of an active pharmaceutical ingredients factory, which will be located in Saint Petersburg, Russia.

The investment follows the signing of a memorandum of understanding between the company and the Russian government at the Saint Petersburg International Economic Forum in June 2017. The project cost is estimated to be around RUB 2bn. The first phase of the plant construction is to launch in the first half of 2019, with a view to be operational by 2020.

Elbrus held a final close for Elbrus Capital Fund II on its $550m hard-cap in February 2014. The Moscow-based GP is focused on Russia and the neighbouring Commonwealth of Independent States (CIS). The firm was launched in 2010 by three industry veterans after they bought out the assets of Renaissance Private Equity from the Renaissance Group at the end of 2009.

Company
Founded in 2002 and based in Saint Petersburg, Active Component manufactures active pharmaceutical substances. It offers generic and original active substances to mainly pharmaceutical manufacturers. Active Component owns a production facility in the Metallostroy district of Saint Petersburg. 

People
Elbrus Capital – Alexander Savin (senior partner). 
Active Component – Alexander Semenov (co-founder, president); Inna Semenova (CEO).

Advisers
Equity – EY (financial due diligence, tax, legal); IQVIA (commercial due diligence).
Company – Duvernoix Legal (legal); Novus Capital (financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• CEE
• Healthcare
• Russia
• Elbrus Capital
• NB Renaissance Partners